Table 1 Baseline characteristics of patients with pitavastatin vs. atorvastatin or rosuvastatin in KDH cohort
| Â | Before PS adjustment | After PS adjustment | ||||
|---|---|---|---|---|---|---|
Pitavastatin (n = 1652) | Atorvastatin + rosuvastatin (n = 5787) | Std. diff | Pitavastatin (n = 1154) | Atorvastatin + rosuvastatin (n = 1876) | Std. diff | |
Age group | ||||||
 20–24 | < 0.3 | 0.3 | − 0.01 | < 0.4 | < 0.2 | − 0.03 |
 25–29 | 0.4 | 0.8 | − 0.05 | 0.4 | 0.9 | − 0.06 |
 30–34 | 1.0 | 1.7 | − 0.06 | 1.0 | 1.3 | − 0.02 |
 35–39 | 1.7 | 3.3 | − 0.10 | 1.7 | 1.9 | − 0.01 |
 40–44 | 4.6 | 4.7 | 0.00 | 4.9 | 5.2 | − 0.01 |
 45–49 | 11.9 | 8.2 | 0.13 | 9.4 | 10.6 | − 0.04 |
 50–54 | 23.2 | 12.9 | 0.27 | 17.4 | 21.0 | − 0.09 |
 55–59 | 20.4 | 15.7 | 0.12 | 20.5 | 17.1 | 0.09 |
 60–64 | 14.5 | 14.1 | 0.01 | 16.0 | 15.4 | 0.02 |
 65–69 | 8.5 | 11.7 | − 0.11 | 10.7 | 9.9 | 0.02 |
 70–74 | 7.1 | 10.7 | − 0.13 | 9.0 | 8.3 | 0.03 |
 75–79 | 3.6 | 7.6 | − 0.18 | 4.9 | 4.2 | 0.03 |
 80–84 | 1.8 | 5.2 | − 0.19 | 2.5 | 2.1 | 0.03 |
 85–89 | 0.8 | 2.4 | − 0.12 | 1.2 | 1.4 | − 0.02 |
 90–94 | < 0.3 | 0.7 | − 0.06 | < 0.4 | 0.5 | − 0.04 |
Female | 76.3 | 54.8 | 0.46 | 67.3 | 71.9 | − 0.10 |
Charlson comorbidity indexa | 0.52 | 0.71 | − 0.19 | 0.56 | 0.52 | 0.03 |
Hyperlipidemia | 17.5 | 17.3 | 0.00 | 17.1 | 17.5 | − 0.01 |
Hypertensive disorder | 26.7 | 29.0 | − 0.05 | 27.1 | 26.0 | 0.02 |
Atrial fibrillation | 1.0 | 1.6 | − 0.05 | 1.4 | 1.1 | 0.03 |
Cerebrovascular disease | 2.9 | 7.7 | − 0.21 | 4.0 | 3.6 | 0.02 |
Heart failure | 1.7 | 3.5 | − 0.11 | 2.3 | 2.0 | 0.02 |
Ischemic heart disease | 5.1 | 13.7 | − 0.30 | 7.0 | 5.8 | 0.05 |
Chronic liver disease | < 0.3 | 0.2 | 0.00 | < 0.4 | < 0.2 | 0.02 |
Chronic obstructive lung disease | 0.7 | 1.3 | − 0.06 | 1.0 | 0.8 | 0.01 |
Renal impairment | 1.2 | 2.1 | − 0.07 | 1.6 | 1.3 | 0.02 |
Gastroesophageal reflux disease | 6.2 | 5.8 | 0.01 | 6.0 | 5.8 | 0.01 |
Osteoarthritis | 1.0 | 1.5 | − 0.04 | 0.7 | 1.1 | − 0.04 |
Dementia | 1.0 | 1.5 | − 0.04 | 0.7 | 1.1 | − 0.04 |
Depressive disorder | 0.5 | 2.3 | − 0.15 | 0.8 | 0.9 | − 0.01 |
Schizophrenia | 1.7 | 2.3 | − 0.04 | 1.7 | 1.8 | − 0.01 |
Visual system disorder | 0.4 | 0.1 | 0.06 | 0.4 | < 0.2 | 0.08 |
Medication use | ||||||
 RAS blocker | 15.9 | 24.0 | − 0.20 | 21.1 | 18.3 | 0.07 |
 Beta blocker | 17.9 | 23.8 | − 0.14 | 22.0 | 21.3 | 0.02 |
 Calcium channel blockers | 10.9 | 16.0 | − 0.15 | 13.5 | 11.9 | 0.05 |
 Diuretics | 15.3 | 21.6 | − 0.16 | 17.6 | 16.0 | 0.04 |
Antibiotics use | 26.0 | 24.3 | 0.04 | 17.3 | 18.6 | − 0.03 |
NSAIDs use | 29.6 | 28.3 | 0.03 | 22.0 | 23.6 | − 0.04 |
Drugs for acid related disorders | 30.8 | 42.7 | − 0.25 | 29.9 | 28.1 | 0.04 |
Drugs for obstructive airway diseases | 3.0 | 5.1 | − 0.11 | 3.1 | 3.6 | − 0.02 |
Immunosuppressants | 1.3 | 1.7 | − 0.04 | 1.5 | 0.8 | 0.06 |